. . "Aeras announced in February that it would begin Phase II trials of two new vaccines against TB. The project has enlisted partnerships with scientists, academic institutions, governments, and companies in Europe, South Africa and other developing countries and the US. A clinical research site is already in operation in Cape Town, South Africa, where more than 9000 volunteers are enrolled in a clini" . . .